Neoadjuvant pembrolizumab with a watch‑and‑wait strategy for localized MSI/dMMR colon cancer: Study protocol for a randomized GERCOR 109 – PRODIGE 84 phase II trial (PREMICES)

20251 citationsJournal Articlehybrid Open Access

Authors

EU‑CT (CTIS) number: 2023‑509322‑22‑00. Registered prior to first patient enrolment.

Published in: Digestive and Liver Disease

Volume 58, Issue 1, pp. 51-55

Field-Weighted Citation Impact: 1.05